Goldman has a new favorite biotech because of potential Alzheimer's blockbuster
August 16, 2017 at 09:18 AM EDT
Goldman Sachs added biotech company Biogen to its Americas Conviction List, citing a 'blockbuster' drug.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.